Polysciences PEI轉染試劑作為目前細(xi)胞與(yu)基因治療用轉染試劑的大熱品(pin)牌(pai)，長(chang)期堅守品(pin)質，已(yi)支持國內多項(xiang)藥物申報(bao)及上市。2024年，Polysciences面向CGT領域成立(li)全資(zi)子(zi)公司(si)Kyfora Bio，獨立(li)運營其PEI轉染與(yu)遞送相關產(chan)品(pin)。

本月下旬，Kyfora Bio將首.次亮相中國展會，與國內友人線下見面！具體出展詳情將在下周由曼博生物為您揭曉，敬請期待下周預告！

生(sheng)物工藝生(sheng)產(chan)放大順序

作(zuo)為(wei)許多(duo)CGT企業(ye)長期信賴的優質(zhi)合(he)作(zuo)伙伴，曼博生物代理產品線(xian)Kyfora Bio by Polysciences具(ju)有(you)多(duo)項優勢：

01   產品性能穩定，具備高度可重復性

Kyfora Bio by Polysciences PEI轉染試劑(ji)可支持(chi)科研(yan)級液體(ti)向GMP等級產(chan)(chan)品的(de)無縫過渡，無需進行工藝(yi)(yi)變更(geng)即可直接實現(xian)商業化生(sheng)產(chan)(chan)；其PEI MAX和(he)Transporter 5被設(she)計(ji)用(yong)于(yu)(yu)病毒(du)載(zai)體(ti)研(yan)發和(he)工藝(yi)(yi)開發過程；MAXgene GMP推薦用(yong)于(yu)(yu)臨床(chuang)試驗及商業化生(sheng)產(chan)(chan)過程，可滿足基(ji)因/細胞治療原料(liao)的(de)質量和(he)監管(guan)要求(qiu)。

Kyfora Bio by Polysciences PEI產品(pin)不同批次(ci)間(jian)保持高度一(yi)致(zhi)性

3個(ge)不同批(pi)次(ci)的(de)PEI轉(zhuan)染試劑(ji)將(jiang)表(biao)達GFP的(de)質粒(li)轉(zhuan)染到(dao)懸浮HEK-293T細胞(bao)中，轉(zhuan)染后48h，通過流式細胞(bao)術(shu)檢測轉(zhuan)染效率。結果表(biao)明，3個(ge)不同批(pi)次(ci)的(de)PEI的(de)轉(zhuan)染效率無較大差(cha)異。

02   細胞毒性低，可維持良好細胞生長狀態

轉(zhuan)染后，轉(zhuan)染試(shi)劑(ji)(ji)的(de)(de)毒(du)性可(ke)能影(ying)響著(zhu)細胞(bao)(bao)生長狀態，很大程度(du)上影(ying)響著(zhu)最終(zhong)的(de)(de)病毒(du)滴(di)度(du)，選擇(ze)適合的(de)(de)轉(zhuan)染試(shi)劑(ji)(ji)能夠盡可(ke)能的(de)(de)減少(shao)因(yin)轉(zhuan)染試(shi)劑(ji)(ji)導致的(de)(de)細胞(bao)(bao)產毒(du)不足。Kyfora Bio by Polysciences轉(zhuan)染試(shi)劑(ji)(ji)具備高(gao).效的(de)(de)轉(zhuan)染能力(li)，同時(shi)兼顧較(jiao)低的(de)(de)毒(du)性，能夠有效減少(shao)對細胞(bao)(bao)的(de)(de)損傷(shang)。

三個不同批(pi)(pi)次(ci)的(de)MAXgene GMP轉染懸浮(fu)HEK-293T細(xi)胞(bao)表達單抗，使(shi)用VI-CELL細(xi)胞(bao)計數儀檢(jian)測轉染后24h和48h的(de)細(xi)胞(bao)活性。數據(ju)顯示，各細(xi)胞(bao)的(de)活力(li)均在90%以上，表明3個不同批(pi)(pi)次(ci)的(de)均保持(chi)(chi)低毒(du)性，且保持(chi)(chi)批(pi)(pi)次(ci)間一致性。

03   轉染性能好，可實現病毒高滴度生產

使用Kyfora Bio by Polysciences PEI轉染懸浮HEK293細胞生(sheng)產(chan)以rAAV8，轉染后48h、72h和96h分(fen)別檢測rAAV8產(chan)量(liang)。結果表明，隨時間增加，產(chan)量(liang)逐(zhu)漸增加，轉染96h后rAAV8滴(di)度(du)可達到約1E12vg/ml。

04   拓展性強、靈活性高

Kyfora Bio by Polysciences PEI轉(zhuan)染試劑可適用于(yu)多種細胞類(lei)型，穩(wen)定支持瞬轉(zhuan)、穩(wen)轉(zhuan)過程，符合商業化需(xu)求，同(tong)時兼容貼(tie)壁及懸浮(fu)培養體系。

除(chu)可支(zhi)持高滴度的病(bing)毒包裝之外，在使(shi)用 HEK293細胞或CHO細胞進行蛋白生產(chan)時，Kyfora Bio by Polysciences PEI也(ye)能夠較其他同(tong)類PEI產(chan)品實現(xian)更高的產(chan)量。

在相(xiang)(xiang)同(tong)(tong)實驗參數下，與其他同(tong)(tong)類(lei)PEI產(chan)(chan)品(pin)相(xiang)(xiang)比，Kyfora Bio by Polysciences PEI轉染試劑(ji)能夠生產(chan)(chan)更高產(chan)(chan)量的抗體。

Polysciences 成立于1961年，憑(ping)借其長期制造獨特、高品(pin)質(zhi)的特種(zhong)化學品(pin)的悠久歷史，已(yi)經成為眾多基因/細胞治療企業值得信賴(lai)的合作伙伴。Kyfora Bio可(ke)提供高品(pin)質(zhi)的科研級和(he)GMP級轉染試劑，支持病毒載(zai)體/蛋白質(zhi)生(sheng)(sheng)產工藝開發到臨床試驗及商業化生(sheng)(sheng)產階段。

參考文獻

1. Aravindan, L., Bicknell, K. A., Brooks, G., Khutoryanskiy, V. V., & Williams, A. C. (2009). Effect of acyl chain length on transfection efficiency and toxicity of polyethylenimine. International journal of pharmaceutics, 378(1-2), 201-210.

2. Dai, Z., Gjetting, T., Mattebjerg, M. A., Wu, C., & Andresen, T. L. (2011). Elucidating the interplay between DNA-condensing and free polycations in gene transfection through a mechanistic study of linear and branched PEI. Biomaterials, 32(33), 8626-8634.

3. Daya, S., & Berns, K. I. (2008). Gene therapy using adeno-associated virus vectors. Clinical microbiology reviews, 21(4), 583-593.

4. Delafosse, L., Xu, P., & Durocher, Y. (2016). Comparative study of polyethylenimines for transient gene expression in mammalian HEK293 and CHO cells. Journal of biotechnology, 227, 103-111.

5. Durymanov, M., & Reineke, J. (2018). Non-viral delivery of nucleic acids: Insight into mechanisms of overcoming intracellular barriers. Frontiers in pharmacology, 9, 971.

6. Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016). Production of recombinant adeno-associated virus vectors using suspension HEK293 cells and continuous harvest of vector from the culture media for GMP FIX and FLT1 clinical vector. Molecular Therapy, 24(2), 287-297.

7. Gu, B., Bhat, V., Dong, W., Pham, H., Pubill, S., Kasaraneni, N., ... & Seth, A. (2018). Establishment of a scalable manufacturing platform for in-silicoderived ancestral adeno-associated virus vectors. Cell and Gene Therapy Insights, 4(S1), 753-769.

8. Milone, M. C., & O’Doherty, U. (2018). Clinical use of lentiviral vectors. Leukemia, 32(7), 1529-1541.

9. Naso, M. F., Tomkowicz, B., Perry, W. L., & Strohl, W. R. (2017). Adeno-associated virus (AAV) as a vector for gene therapy. BioDrugs, 31(4), 317-334.

10. Nimesh, S., Aggarwal A., Kumar, P., Singh, Y., Gupta, K., Chandra, R. (2006). Influence of acyl chain length on transfection mediated by acylated PEI nanoparticles. Int J Pharm. 7;337(1-2), 265-74.

11. Sawant, R. R., Sriraman, S. K., Navarro, G., Biswas, S., Dalvi, R. A., & Torchilin, V. P. (2012). Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials, 33(15), 3942-3951.

12. Sun, W., Zheng, W., & Simeonov, A. (2017). Drug discovery and development for rare genetic disorders. American Journal of Medical Genetics Part A, 173(9), 2307-2322.

13. Zakeri, A., Kouhbanani, M. A. J., Beheshtkhoo, N., Beigi, V., Mousavi, S. M., Hashemi, S. A. R., ... & Movahedpour, A. (2018). Polyethylenimine-based nanocarriers in co-delivery of drug and gene: a developing horizon. Nano reviews & experiments, 9(1), 1488497.